DERM Stock — Journey Medical Corporation: Cash, EV, Pipeline

Share price

$7.31

Market cap

$206.3M

Cash

$25.6M

Enterprise value

$201.1M

Balance sheet

Cash	$25.6M
Debt	$20.5M
Net cash	$5.2M
Enterprise value	$201.1M
Basic shares	27.5M shares
Fully diluted shares	26.1M shares
Fully diluted market cap	$190.8M
Cash per share	$0.93

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading DERM daily closes…

Loading price history…

Pipeline assets

Emrosi

Approved · Active Modality: oral modified-release capsule (minocycline hydrochloride 40 mg)

Aliases DFD-29

Partnerships Dr. Reddy's Laboratories: global rights (DRL retained select markets); $10M upfront, $3M NDA-acceptance milestone, $15M approval milestone; up to $150M contingent milestones; 10-14% royalties

Indications

Inflammatory lesions of rosacea in adults (Approved)

Status note FDA approved November 1, 2024 under 505(b)(2). Company also markets several other dermatology products (Amzeeq, Zilxi, Qbrexza, Accutane, Exelderm, Luxamend).

FCD105

Stage not disclosed · Active

Partnerships Vyne Therapeutics: acquired via $20M-upfront asset purchase (Molecule Stabilizing Technology franchise)

Indications

Dermatology (specific indication not stated) (Stage not disclosed)

Status note Development-stage dermatology program acquired from Vyne in January 2022; filing discloses no phase, indication, or development status beyond its acquisition.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07462702	Early Phase 1	Not yet recruiting	Collaborator	Medical University of South Carolina	—	Confluent and Reticulated Papillomatosis (CARP)	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Medical University of South Carolina on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

DERM — Journey Medical Corporation

Balance sheet

Price history

Pipeline assets

Active clinical trials